Efficacy of Alternate-Day Dosing House dust mite Sublingual Immunotherapy Compared to Daily Dosing in Allergic Rhinitis Patients

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

TCTR

Registry ID

TCTR20250107010

Enrollment

Registered

2025-01-07

Start date

2025-03-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic rhinitis Allergic rhinitis House dust mite sublingual immunotherapy AR HDM SLIT

Interventions

12SQ HDM SLIT with alternate day dosing,12SQ HDM SLIT with daily dosing

Experimental Drug,Active Comparator Drug

Alternate day dosing,Daily dosing

Eligibility

Sex/Gender

All

Age

20 Years to 65 Years

Inclusion criteria

Inclusion criteria: Age 20-65 years Diagnosed with allergic rhinitis Tested positive for HDM sensitization (skin prick test or serum specific IgE) Undergoing HDM SLIT for more than 6 months and not exceeding 3 years

Exclusion criteria

Exclusion criteria: Diagnosed with nasal polyp or deviated nasal septum Advanced systemic disease (heart failure, cirrhosis, ESRD) Pregnancy or lactation Prior URI within 2 weeks Prior systemic glucoticosteriod use within 8 weeks

Design outcomes

Primary

Measure	Time frame
TCRS 0,3,6 month Symptoms amd medication score questionaire	—

Secondary

Measure	Time frame
Specific IgG4 for Dp 0,6 month Blood test,Total IgE 0,6 month Blood test,Quality of life 0,3,6 month mini rhinoconjunctivitis quality of life questionnaire,Adverse event 0,3,6 month Naranjo algorithm,Specific IgE for Dp/Df 0,6 month Blood test	—

Countries

Thailand

Contacts

Public ContactPhramongkutklao hospital OPD Allergic

Internal medicine department

pmkmedallergy@gmail.com02763000

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026